Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
567.2 GBX | -0.04% | +1.12% | -4.30% |
07/05 | Barclays Reduces Fresnillo PT, Maintains Equalweight Rating | MT |
07/05 | AstraZeneca target raised; Antofagasta lowered | AN |
Sales 2024 * | 2.96B 247B | Sales 2025 * | 2.99B 250B | Capitalization | 5.25B 438B |
---|---|---|---|---|---|
Net income 2024 * | 245M 20.46B | Net income 2025 * | 326M 27.22B | EV / Sales 2024 * | 1.81 x |
Net Debt 2024 * | 98.49M 8.22B | Net cash position 2025 * | 187M 15.63B | EV / Sales 2025 * | 1.69 x |
P/E ratio 2024 * |
21.4
x | P/E ratio 2025 * |
16.1
x | Employees | 7,260 |
Yield 2024 * |
2.01% | Yield 2025 * |
2.87% | Free-Float | 25% |
Latest transcript on Fresnillo plc
1 day | -0.04% | ||
1 week | +1.12% | ||
Current month | +1.94% | ||
1 month | +2.31% | ||
3 months | +15.33% | ||
6 months | +4.99% | ||
Current year | -4.30% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 15/12/15 | |
Director of Finance/CFO | 76 | 15/08/15 | |
Chief Operating Officer | - | 19/20/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 16/12/16 | |
Director/Board Member | 57 | 16/14/16 | |
Director/Board Member | 80 | 15/08/15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.14% | 36 M€ | -4.07% | - | |
0.04% | 0 M€ | +6.60% | - |
Date | Price | Change | Volume |
---|---|---|---|
08/24/08 | 568.8 | +0.23% | 19 340 |
07/24/07 | 567.5 | +3.28% | 1,583,818 |
03/24/03 | 549.5 | -1.52% | 696,241 |
02/24/02 | 558 | -0.80% | 854,013 |
01/24/01 | 562.5 | +0.81% | 763,048 |
Delayed Quote London S.E., May 08, 2024 at 01:00 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.30% | 5.25B | |
-13.95% | 146B | |
-5.01% | 120B | |
-1.65% | 71.33B | |
+2.16% | 48.8B | |
+10.78% | 48.78B | |
+36.05% | 40.77B | |
+23.39% | 26.19B | |
+47.83% | 22.57B | |
+57.92% | 17.62B |
- Stock Market
- Equities
- FRES Stock